Phase III DAYBREAK study found consistent safety with Zeposia in patients with relapsing forms of multiple sclerosis.
Bristol Myers Squibb Reveals Promising Results from Trial of Zeposia for Multiple Sclerosis
Phase III DAYBREAK study found consistent safety with Zeposia in patients with relapsing forms of multiple sclerosis.